English – Alligator Bioscience

2025-09-10

Alligator announces publication in Cancer Immunology Research of preclinical data on ATOR-4066, a tumor-directed CD40×CEACAM5 bispecific antibody

Lund, Sweden – 10 September 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company develo ...

2025-09-08

Regulatory

Alligator Bioscience has renegotiated the outstanding loan from Fenja Capital and received subscription intentions from members of the Board of Directors and management

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, HONG KONG, J ...

2025-09-08

Grant awarded to investigator-initiated Phase 2/3 trial with mitazalimab in biliary tract cancer

Lund, Sweden – 8 September 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company develop ...

2025-09-05

Alligator Bioscience to present at BioStock’s “Investing in Life Science” event

Lund, Sweden – 5 September 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company develop ...

2025-09-02

Alligator announces evaluation and option agreement covering RUBY™ antibody format

Lund, Sweden – 2 September 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that Alligator has entered into ...

2025-08-27

Regulatory

Exercise price determined for the exercise of warrants series TO 13 in Alligator Bioscience AB

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...

2025-08-20

Alligator Bioscience provides highlights from R&D event 2025

Lund, Sweden – 20 August 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developin ...

2025-08-14

Alligator Bioscience to host virtual R&D Day on 19 August 2025

Lund, Sweden – 14 August 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developin ...

2025-07-25

Alligator Bioscience announces upcoming presentation of REACtiVe-2 Phase 1 data at ESMO Congress 2025

Lund, Sweden – 25 July 2025 – Alligator Bioscience (Nasdaq Stockholm: ATORX), a clinical-stage biotechnology company developing ...